There is no corporate support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Medical Students
Residents and Fellows
Faculty Physicians
Allied Health Providers

NEEDS ASSESSMENT
In the past we have treated patients with CF with treatments focusing on their symptoms. We are now entering an era where therapies focus on treating the underlying defect. With small molecule therapies we are able to make the most of a mutant protein. Moving forward genetic therapies will need to be developed to treat our patients. These innovative technologies including RNA therapies, gene therapies and gene editing technologies are moving towards the clinical realm at an unexpected pace. They hold the key for “a cure for all with CF”. However, moving from the promise of these technologies to the reality of effective therapy and care for all will require time, tenacity and vision.

LEARNING OBJECTIVES
At the end of this activity, participants will be able to:
1. Review new therapies and the promise they hold for patients with CF
2. Review emerging genetic therapies and the promise they hold for patients with CF
3. Discuss/Describe the unique challenges we face regarding delivering these therapies in CT

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Marie Egan, MD: TBD
Pnina Weiss, MD, Grand Rounds Director: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.